JAC Advance Access originally published online on February 10, 2005
Journal of Antimicrobial Chemotherapy 2005 55(3):283-288; doi:10.1093/jac/dkh546
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
JAC vol.55 no.3 © The British Society for Antimicrobial Chemotherapy 2005; all rights reserved
Leading article |
Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections
Cubist Pharmaceuticals, Inc., 65 Hayden Avenue, Lexington, MA 02421, USA
* Corresponding author. Tel: +1-781-860-8434; Fax: +1-781-861-1164; Email: judith.steenbergen{at}cubist.com
Infections caused by drug-resistant pathogens are on the rise. Daptomycin, a cyclic lipopeptide with activity against most Gram-positive pathogens, including vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus, is a newly US-FDA approved antimicrobial for complicated skin and skin structure infections (cSSSI). Daptomycin has a unique mechanism of action that results in destruction of the membrane potential. The rapid bactericidal activity of daptomycin makes it an attractive antibiotic for serious Gram-positive infections.
Keywords: MRSA , cSSSI , vancomycin
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  O. Murillo, C. Garrigos, M. E. Pachon, G. Euba, R. Verdaguer, C. Cabellos, J. Cabo, F. Gudiol, and J. Ariza Efficacy of High Doses of Daptomycin versus Alternative Therapies against Experimental Foreign-Body Infection by Methicillin-Resistant Staphylococcus aureus Antimicrob. Agents Chemother., October 1, 2009; 53(10): 4252 - 4257. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.-K. John, D. Baldoni, M. Haschke, K. Rentsch, P. Schaerli, W. Zimmerli, and A. Trampuz Efficacy of Daptomycin in Implant-Associated Infection Due to Methicillin-Resistant Staphylococcus aureus: Importance of Combination with Rifampin Antimicrob. Agents Chemother., July 1, 2009; 53(7): 2719 - 2724. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Schoen, C. Unzicker, G. Stuhler, J. Elias, H. Einsele, G. U. Grigoleit, M. Abele-Horn, and S. Mielke Life-Threatening Infection Caused by Daptomycin-Resistant Corynebacterium jeikeium in a Neutropenic Patient J. Clin. Microbiol., July 1, 2009; 47(7): 2328 - 2331. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. M. Hawkey Pre-clinical experience with daptomycin J. Antimicrob. Chemother., November 1, 2008; 62(suppl_3): iii7 - iii14. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. M. Amsler, T. A. Davies, W. Shang, M. R. Jacobs, and K. Bush In Vitro Activity of Ceftobiprole against Pathogens from Two Phase 3 Clinical Trials of Complicated Skin and Skin Structure Infections Antimicrob. Agents Chemother., September 1, 2008; 52(9): 3418 - 3423. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. I. Hidron, A. N. Schuetz, F. S. Nolte, C. V. Gould, and M. K. Osborn Daptomycin resistance in Enterococcus faecalis prosthetic valve endocarditis J. Antimicrob. Chemother., June 1, 2008; 61(6): 1394 - 1396. [Full Text] [PDF]
|
|
|
|
|
|
L. Spanjaard and C. M. J. E. Vandenbroucke-Grauls Activity of Daptomycin against Listeria monocytogenes Isolates from Cerebrospinal Fluid Antimicrob. Agents Chemother., May 1, 2008; 52(5): 1850 - 1851. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L. Baltch, W. J. Ritz, L. H. Bopp, P. Michelsen, and R. P. Smith Activities of Daptomycin and Comparative Antimicrobials, Singly and in Combination, against Extracellular and Intracellular Staphylococcus aureus and Its Stable Small-Colony Variant in Human Monocyte-Derived Macrophages and in Broth Antimicrob. Agents Chemother., May 1, 2008; 52(5): 1829 - 1833. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Shea, E. Hilburger, A. Baroco, and E. Oldfield Successful Treatment of Vancomycin-Resistant Enterococcus faecium Pyelonephritis with Daptomycin During Pregnancy Ann. Pharmacother., May 1, 2008; 42(5): 722 - 725. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-T. Huang, C.-H. Hsiao, C.-H. Liao, C.-W. Lee, and P.-R. Hsueh Bacteremia and Infective Endocarditis Caused by a Non-Daptomycin-Susceptible, Vancomycin-Intermediate, and Methicillin-Resistant Staphylococcus aureus Strain in Taiwan J. Clin. Microbiol., March 1, 2008; 46(3): 1132 - 1136. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. P. Zavascki, L. Z. Goldani, J. Li, and R. L. Nation Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review J. Antimicrob. Chemother., December 1, 2007; 60(6): 1206 - 1215. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A Mergenhagen and M. T Pasko Daptomycin Use After Vancomycin-Induced Neutropenia in a Patient with Left-Sided Endocarditis Ann. Pharmacother., September 1, 2007; 41(9): 1531 - 1535. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. H. Rand, H. J. Houck, and J. A. Silverman Daptomycin-reversible rifampicin resistance in vancomycin-resistant Enterococcus faecium J. Antimicrob. Chemother., May 1, 2007; 59(5): 1017 - 1020. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Credito, G. Lin, and P. C. Appelbaum Activity of Daptomycin Alone and in Combination with Rifampin and Gentamicin against Staphylococcus aureus Assessed by Time-Kill Methodology Antimicrob. Agents Chemother., April 1, 2007; 51(4): 1504 - 1507. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L. Baltch, W. J. Ritz, L. H. Bopp, P. B. Michelsen, and R. P. Smith Antimicrobial Activities of Daptomycin, Vancomycin, and Oxacillin in Human Monocytes and of Daptomycin in Combination with Gentamicin and/or Rifampin in Human Monocytes and in Broth against Staphylococcus aureus Antimicrob. Agents Chemother., April 1, 2007; 51(4): 1559 - 1562. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Vouillamoz, P. Moreillon, M. Giddey, and J. M. Entenza Efficacy of daptomycin in the treatment of experimental endocarditis due to susceptible and multidrug-resistant enterococci J. Antimicrob. Chemother., December 1, 2006; 58(6): 1208 - 1214. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. L. French Bactericidal agents in the treatment of MRSA infections--the potential role of daptomycin J. Antimicrob. Chemother., December 1, 2006; 58(6): 1107 - 1117. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. DeRyke, C. Sutherland, B. Zhang, D. P. Nicolau, and J. L. Kuti Serum Bactericidal Activities of High-Dose Daptomycin with and without Coadministration of Gentamicin against Isolates of Staphylococcus aureus and Enterococcus species Antimicrob. Agents Chemother., November 1, 2006; 50(11): 3529 - 3534. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Makovitzki, D. Avrahami, and Y. Shai Ultrashort antibacterial and antifungal lipopeptides PNAS, October 24, 2006; 103(43): 15997 - 16002. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Citron and M. D. Appleman In Vitro Activities of Daptomycin, Ciprofloxacin, and Other Antimicrobial Agents against the Cells and Spores of Clinical Isolates of Bacillus Species. J. Clin. Microbiol., October 1, 2006; 44(10): 3814 - 3818. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. A. Jevitt, G. M. Thorne, M. M. Traczewski, R. N. Jones, J. E. McGowan Jr., F. C. Tenover, and S. D. Brown Multicenter Evaluation of the Etest and Disk Diffusion Methods for Differentiating Daptomycin-Susceptible from Non-Daptomycin-Susceptible Staphylococcus aureus Isolates. J. Clin. Microbiol., September 1, 2006; 44(9): 3098 - 3104. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Denis, A. Deplano, C. Nonhoff, M. Hallin, R. De Ryck, R. Vanhoof, R. De Mendonca, and M. J. Struelens In Vitro Activities of Ceftobiprole, Tigecycline, Daptomycin, and 19 Other Antimicrobials against Methicillin-Resistant Staphylococcus aureus Strains from a National Survey of Belgian Hospitals. Antimicrob. Agents Chemother., August 1, 2006; 50(8): 2680 - 2685. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. K. English, E. M. Maryniw, A. J. Talati, and E. A. Meals Diminished Macrophage Inflammatory Response to Staphylococcus aureus Isolates Exposed to Daptomycin versus Vancomycin or Oxacillin. Antimicrob. Agents Chemother., June 1, 2006; 50(6): 2225 - 2227. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. M. Marty, W. W. Yeh, C. B. Wennersten, L. Venkataraman, E. Albano, E. P. Alyea, H. S. Gold, L. R. Baden, and S. K. Pillai Emergence of a Clinical Daptomycin-Resistant Staphylococcus aureus Isolate during Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia and Osteomyelitis J. Clin. Microbiol., February 1, 2006; 44(2): 595 - 597. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Skiest Treatment Failure Resulting from Resistance of Staphylococcus aureus to Daptomycin J. Clin. Microbiol., February 1, 2006; 44(2): 655 - 656. [Abstract] [Full Text] [PDF]
|
|